Core Viewpoint - Ventripoint Diagnostics Ltd. will fulfill its debenture interest payment obligations by issuing common shares, pending approval from the TSX Venture Exchange [1] Group 1: Financial Details - The company will issue a total of 1,145,627 common shares to cover $103,106.29 in interest on outstanding Convertible Debentures [1] - The Convertible Debentures carry an interest rate of 10% per annum, with payments due every six months [1] - The shares will be issued at a deemed price of $0.089 and will be subject to a hold period of 4 months and one day [1] Group 2: Company Overview - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS products utilizing proprietary knowledge-based reconstruction technology [2] - This technology provides accurate volumetric cardiac measurements comparable to MRI, offering a cost-effective alternative for cardiologists [2] - VMS+ is compatible with all ultrasound systems from various vendors and has received regulatory market approvals in the U.S., Europe, and Canada [2]

Core Insights - Ventripoint Diagnostics Ltd. has agreed to settle $542,591.50 of debt by issuing 5,425,915 common shares at a price of $0.10 per share [1][2] - The share issuance is intended to preserve cash for business development and is subject to approval by the TSX Venture Exchange [2] Company Overview - Ventripoint is a leader in applying AI to echocardiography, with its VMS products utilizing proprietary knowledge-based reconstruction technology for accurate volumetric cardiac measurements comparable to MRI [4] - The VMS+ product is versatile and compatible with all ultrasound systems, supported by regulatory approvals in the U.S., Europe, and Canada [4]